Última actualización:
7/23/2024
Años publicados: 2004, 2007, 2014, 2017, 2020, 2024
NORD gratefully acknowledges Ingo Kurth, MD, Institute for Human Genetics and Genomic Medicine, RWTH Aachen University, Aachen, Germany, for assistance in the preparation of this report.
Summary
Hereditary sensory and autonomic neuropathy type IV (HSAN4 or HSAN IV) is a rare genetic disorder that usually begins in infancy and is characterized by an inability to feel pain and an inability to sweat (anhidrosis). Affected individuals also cannot feel temperature and cannot distinguish between hot and cold. The sensory loss in individuals with HSAN IV is due to abnormal functioning of the sensory nerves that control responses to pain and temperature. Anhidrosis can cause recurrent episodes of fever and high body temperature. An inability to feel pain can lead to unintentional self-mutation, repeated fractures and joint damage. Affected individuals and especially children or infants may be unaware of injury delaying treatment. HSAN IV is caused by changes (variants) in the NTRK1 gene. The disorder is inherited in an autosomal recessive pattern.
Introduction
The hereditary sensory and autonomic neuropathies (HSAN), also known as the hereditary sensory neuropathies, include distinct inherited degenerative disorders of the nervous system (neurodegenerative) that frequently progress to loss of feeling, especially in the hands and feet. Some of these disorders have several subtypes based upon the specific associated genes and variants in about 20 genes have been identified as disease-causative. Some types of HSAN are related to or identical with some forms of Charcot-Marie-Tooth disease and others are related to or identical with familial dysautonomia (Riley-Day syndrome). The classification of the HSANs is complicated, and the experts do not always agree on it. Furthermore, HSANs are classified more broadly as peripheral neuropathies or disorders or the peripheral nervous system, which encompasses all the nerves outside of the central nervous system (i.e. brain and spinal cord). HSAN IV is also known as congenital insensitivity to pain with anhidrosis (CIPA).
Infants with HSAN IV cannot sweat or have a markedly decreased ability to sweat (anhidrosis). Sweating is the body’s way of cooling itself and maintaining proper body temperature. The inability to sweat can cause recurrent episodes of fever including extremely high fevers that result in a significant elevation of body temperature (hyperpyrexia). When someone has a significantly increased body temperature it is known as hyperthermia, and this can be the initial sign of the disorder. The inability to sweat can affect the entire body, but the trunk and arms are mostly affected. Seizures are sometimes associated with fever episodes. The skin may become abnormally thickened and callused with an exaggeration of normal skin lines (lichenification). There may be areas of hair loss of the scalp (hypotrichosis) and malformation of the fingernails and toenails.
Affected infants fail to feel pain in response to stimuli that normally should produce pain such as failing to respond to routine injections that are part of pediatric immunizations. Pain is essential to protect people from injury and to alert the body of injury. Because of the inability to feel pain, affected infants and children may suffer repeated injuries and may have behaviors that cause injury to themselves (self-mutilation) including biting one’s tongue, lips and the lining of the inside of the mouth (buccal mucosa). Affected infants often develop ulcers on their tongues from repeatedly biting their tongues. When the primary teeth first erupt, affected children often bite their fingertips or toes; in severe cases, they can chew or bite off the tips of their fingers or toes.
Affected individuals will be unable to distinguish between cold or warm stimuli and be unable to feel pain in the affected area. Because of the loss of sensation, affected individuals may be unaware of injury. For example, affected individuals may develop chronic skin erosions, ulcers (open sores) or blisters that are slow to heal. These normally painful conditions do not hurt because of the loss of sensation. If unrecognized and left untreated, these painless injuries can progress to cause more serious complications such as recurrent infections. Eventually, affected individuals can develop infection of the surrounding bone (osteomyelitis), loss of bone and tissue in the fingers and toes (acroosteolysis) and spontaneous, repeated fractures. Repeated trauma to joints results in progressive inflammation, damage and deformity of the affected joints (Charcot joint or neuropathic arthropathy). The large, weight-bearing joints are especially prone to this complication.
Children with HSAN IV may show delays in attaining developmental milestones (developmental delays) and learning disabilities are common. Intellectual disability has been reported in some people, but the severity varies widely, and some children are only mildly affected. Behavioral problems including irritability, hyperactivity, inability to control one’s emotions (emotional lability) and episodes of anger or rage have also been reported.
Diminished muscle tone (hypotonia) may be present at birth or during infancy. Hypotonia, also known as a “floppy baby,” may cause affected infants to be abnormally limp. Although hypotonia is common at birth, strength and tone improves with age.
Some individuals experience postural hypotension, a condition in which there is a drop in blood pressure upon a change in body position such as upon standing. Sometimes, postural hypotension is accompanied by a faster than normal heart rate (compensatory tachycardia), in which the body attempts to compensate for the decreased blood pressure.
Eye abnormalities may develop, specifically neurotrophic keratitis, a condition characterized by damage to the corneas of the eyes. The cornea is the transparent membrane that covers the front of the eyes. Affected individuals can develop lesions (ulcerations) on the cornea; these lesions can cause corneal scarring. Infection can also occur.
HSAN IV is caused by variants in the neurotrophic receptor tyrosine kinase 1 (NTRK1) gene. Genes provide instructions for creating proteins that play a critical role in many functions of the body. When a variant in a gene occurs, the protein product may be faulty, inefficient or absent. Depending upon the functions of the protein, this can affect many organ systems of the body.
The NTRK1 gene creates (encodes) neurotrophic receptor tyrosine kinase 1, a protein that is found on the surface of certain cells, especially nerve cells (neurons) that transmit pain, temperature and touch sensations. Another protein known as nerve growth factor (NGF) binds to the NTRK1 receptor, which allows nerve signals that are essential for the growth and survival of the cell to be transmitted into the cell. Variants in the NTRK1 gene result in faulty or deficient neurotrophic receptor tyrosine kinase 1, which impairs NGF signaling and, consequently, the transmission of nerve signals. Ultimately, the affected neurons die prematurely or during disease progression. The symptoms of HSAN IV result from the impairment of sensory nerve cells.
HSAN IV is inherited in an autosomal recessive pattern. Recessive genetic disorders occur when an individual inherits a disease-causing gene variant from each parent. If an individual receives one normal gene and one disease-causing gene variant, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the gene variant and have an affected child is 25% with each pregnancy. The risk of having a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents is 25%. The risk is the same for males and females.
HSAN IV affects males and females in equal numbers. Around one hundred cases have been reported in the medical literature. The exact incidence and prevalence are unknown with few exceptions. In the UK, HSAN IV has an approximate prevalence of 1 in 500,000 to 1 in 1,000,000 individuals and in Japan the prevalence is estimated as 1 in 600,000 to 1 in 950,000, 6. The frequency of the disorder is higher in the Israeli-Bedouin populations due to a founder effect. A founder effect is when a small, isolated population of settlers (founders) expands over several generations leading to a high prevalence of a particular genetic trait. Regions with a high rate of consanguinity also show a higher prevalence.
A diagnosis is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests, mainly genetic testing. Characterized symptoms proposed as necessary for a diagnosis are insensitivity to pain, anhidrosis and intellectual disability. However, the severity of these symptoms is highly variable.
Clinical Testing and Workup
Surgical removal and microscopic examination of affected skin tissue (skin biopsy) may reveal a lack of functioning nerves supplying the sweat glands (eccrine sweat gland innervation). A biopsy of nerve tissue from the calf of the leg (sural nerve biopsy) may reveal characteristic findings including reduced numbers of myelinated and unmyelinated small-diameter fibers with normal numbers of large-diameter fibers but is largely replaced by molecular genetic testing.
An axonal flare test is sometimes used to aid in diagnosing HSAN IV. During this test, a small amount of diluted histamine is injected underneath the skin. Histamine is a chemical compound produced by the body that helps the immune system and acts as a neurotransmitter (a chemical that modifies, amplifies or transmits nerve impulses from one nerve cell to another). An injection of histamine causes a distinctive skin eruption around the site of injection.
Molecular genetic testing for variants in the NTRK1 gene can confirm the diagnosis and is often done by next-generation sequencing (NGS) from a blood sample.
Treatment
Treatment is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists. Pediatricians, dermatologists, neurologists, dental specialists, orthopedists, ophthalmologists, and other healthcare professionals may need to plan for an affect child’s treatment systematically and comprehensively. Psychosocial support for the entire family is essential as well.
Genetic counseling is recommended for affected individuals and their families.
Affected individuals may be treated with acetaminophen or ibuprofen when fevers are present. Direct cooling in a bath or with a blanket designed to lower body temperature (cooling blanket) may also be used.
Various orthopedic measures may be necessary to treat abnormalities affecting the bones and joints including surgery or the use of braces or orthopedic devices.
Various dental procedures may be used to treat individuals. Smoothing over or grinding down the sharp edges of teeth, prophylactic use of crowns, the use of a night-guard and other orthodontic treatments may be considered. Extracting teeth to prevent self-mutilation has also been done.
Treatment of neurotrophic keratitis can include a procedure in which the eyelids are sewn together to narrow the opening (tarsorrhaphy), plastic surgery to repair the cornea (keratoplasty), replacement of part or all of an affected cornea with healthy corneal tissue from a donor (scleral corneal graft) and special contact lenses that protect the cornea (scleral bandage lens). These contact lenses create a space between the front of the cornea and the back of the lenses that fills with a sterile saline solution.
Behavioral issues tend to improve with age. These issues have been treated with behavior modification techniques along with anti-psychotic medications or attention deficit hyperactivity disorder medications.
Regular, daily inspection for unrecognized or unrealized injury is important as well.
Several researchers are interested in HSAN disorders and offer genetic testing, e.g. on a research basis for individuals meeting the criteria for a diagnosis of HSAN. For more information, contact:
Prof. Dr. med. Ingo Kurth
Institute for Human Genetics and Genomic Medicine
Uniklinik RWTH Aachen
Pauwelsstr. 30
52074 Aachen
[email protected]
Tel. +49-241-8080178
FAX +49-241-8082580
A European Network on Inherited Sensory Neuropathies and Insensitivity to Pain is available: https://enisnip.org/
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Toll-free: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]
Some current clinical trials also are posted on the following page on the NORD website:
https://rarediseases.org/living-with-a-rare-disease/find-clinical-trials/
For information about clinical trials sponsored by private sources, in the main, contact: www.centerwatch.com
For more information about clinical trials conducted in Europe, contact: https://www.clinicaltrialsregister.eu/
JOURNAL ARTICLES
Haga N, Kubota M, Miwa Z. Epidemiology of hereditary sensory and autonomic neuropathy type IV and V in Japan. Am J Med Genet A. 2013;161:871-874. http://www.ncbi.nlm.nih.gov/pubmed/23495212
Dias E, Charki S. Congenital insensitivity to pain with anhidrosis. J Pediatr Neurosci. 2012;7:156-157. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519084/
Indo Y. Nerve growth factor and the physiology of pain: lessons from congenital insensitivity to pain with anhidrosis. Clin Genet. 2012;82:341-350. http://www.ncbi.nlm.nih.gov/pubmed/22882139
Sarasola E, Rodriguez JA, Garrote E, Aristegui J, Garcia-Barcina MJ. A short in-frame deletion in NTRK1 tyrosine kinase domain caused by a novel splice site mutation in a patient with congenital insensitivity to pain with anhidrosis. BMC Med Genet. 2011;12:88. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141629/
Rotthier A, Baets J, de Vriendt E, et al. Genes for hereditary sensory and autonomic neuropathies: a genotype-phenotype correlation. Brain. 2009;132:2699-2711. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759337/
Axelrod FB, Gold-von Simson G. Hereditary sensory and autonomic neuropathies: types II, III, and IV. Orphanet J Rare Dis. 2007;2:39. Published 2007 Oct 3. doi:10.1186/1750-1172-2-39
Verhoeven K, Timmerman V, Mauko B, et al. Recent advances in hereditary sensory and autonomic neuropathies. Curr Opin Neurol. 2006;19:474-480. http://www.ncbi.nlm.nih.gov/pubmed/16969157
Nagasako EM, Oaklander AL, Dworkin RH. Congenital insensitivity to pain: an update. Pain. 2003;101:213-219. http://www.ncbi.nlm.nih.gov/pubmed/12583863
INTERNET
Schon KR, Parker APJ, Woods CG. Congenital Insensitivity to Pain Overview. 2018 Feb 8 [Updated 2020 Jun 11]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK481553/ Accessed May 14, 2024.
Indo Y. NTRK1 Congenital Insensitivity to Pain with Anhidrosis. 2008 Aug 5 [Updated 2020 Apr 30]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1769/ Accessed May 14, 2024.
Kurth I. Hereditary Sensory and Autonomic Neuropathy Type II. 2010 Nov 23 [Updated 2021 Apr 1]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK49247/ Accessed May 14, 2024.
Eichler FS. Hereditary Sensory and Autonomic Neuropathies. Last Update May 02, 2023. Available at: http://www.uptodate.com/contents/hereditary-sensory-and-autonomic-neuropathies Accessed May 14, 2024.
NORD y la Fundación MedicAlert se han asociado en un nuevo programa para brindar protección a pacientes con enfermedades raras en situaciones de emergencia.
Aprende más https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/Asegurarse de que los pacientes y los cuidadores estén equipados con las herramientas que necesitan para vivir su mejor vida mientras manejan su condición rara es una parte vital de la misión de NORD.
Aprende más https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/Este programa de asistencia, primero en su tipo, está diseñado para los cuidadores de un niño o adulto diagnosticado con un trastorno raro.
Aprende más https://rarediseases.org/patient-assistance-programs/caregiver-respite/The information provided on this page is for informational purposes only. The National Organization for Rare Disorders (NORD) does not endorse the information presented. The content has been gathered in partnership with the MONDO Disease Ontology. Please consult with a healthcare professional for medical advice and treatment.
The Genetic and Rare Diseases Information Center (GARD) has information and resources for patients, caregivers, and families that may be helpful before and after diagnosis of this condition. GARD is a program of the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
View reportOrphanet has a summary about this condition that may include information on the diagnosis, care, and treatment as well as other resources. Some of the information and resources are available in languages other than English. The summary may include medical terms, so we encourage you to share and discuss this information with your doctor. Orphanet is the French National Institute for Health and Medical Research and the Health Programme of the European Union.
View reportOnline Mendelian Inheritance In Man (OMIM) has a summary of published research about this condition and includes references from the medical literature. The summary contains medical and scientific terms, so we encourage you to share and discuss this information with your doctor. OMIM is authored and edited at the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine.
View report